BioRestorative Therapies
NASDAQ: BRTXMelville, US · Nevada corporation
Biotech
Founders & leadership
RK
Robert KristalExecutive Officer
FS
Francisco SilvaDirector, Executive Officer
LA
Lance AlstodtDirector, Executive Officer
EL
Edward L. FieldPresident, Disc/Spine Division
PJ
Paul Jude TonnaDirector
RB
Robert B. CatellDirector
AJ
A. Jeffrey RadovDirector
JM
John M. DesmaraisDirector
CS
Charles S. RyanDirector
MC
Mandy ClydeVice President of Operations and Secretary
MW
Mark WeinrebChief Executive Officer, Chairman of the Board and President
NV
Nickolay V KukekovDirector
Reported raises · per SEC filings
Form D private placements▶$1.4MraisedOct 2025 · 16 investors · BiotechnologyRule 506(b)
▶$1.4MraisedOct 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nickolay V KukekovDirector
- Robert KristalExecutive Officer
- Francisco SilvaDirector, Executive Officer
- Patrick F WilliamsDirector
- David A RosaDirector
- Lance AlstodtDirector, Executive Officer
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Placement agents
- Cova Capital Partners LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$14.4MraisedMay 2016 · 81 investors · BiotechnologyRule 506(b)
▶$14.4MraisedMay 2016 · 81 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward L. FieldExecutive Officer
- Francisco SilvaExecutive Officer
- Paul Jude TonnaDirector
- Robert B. CatellDirector
- A. Jeffrey RadovDirector
- John M. DesmaraisDirector
- Charles S. RyanDirector
- Mandy ClydeExecutive Officer
- Mark WeinrebExecutive Officer, Director
- Amount sold
- $14.4M
- Proceeds to insiders
- $2.7M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $256.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.